Galsky MD - Search Results

1

Heterogeneity in Methods of Estimating Kidney Function for Cancer Clinical Trial Eligibility.

Karol AB, Paredes R, Fujiwara Y, Argulian A, Joshi H, Abramson M, Galsky MD. Karol AB, et al. Among authors: galsky md. JAMA Netw Open. 2024 Sep 3;7(9):e2433387. doi: 10.1001/jamanetworkopen.2024.33387. JAMA Netw Open. 2024. PMID: 39283642 Free PMC article.

2

Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer.

Tsao CK, Moshier E, Seng SM, Godbold J, Grossman S, Winston J, Oh WK, Galsky MD. Tsao CK, et al. Among authors: galsky md. Clin Genitourin Cancer. 2012 Mar;10(1):15-20. doi: 10.1016/j.clgc.2011.10.004. Epub 2011 Nov 29. Clin Genitourin Cancer. 2012. PMID: 22130294

3

Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis.

Dahal A, Bellows BK, Sonpavde G, Tantravahi SK, Choueiri TK, Galsky MD, Agarwal N. Dahal A, et al. Among authors: galsky md. Am J Clin Oncol. 2016 Oct;39(5):497-506. doi: 10.1097/COC.0000000000000081. Am J Clin Oncol. 2016. PMID: 24824144 Review.

4

Mind the gap: efficacy versus effectiveness and pivotal prostate cancer clinical trial demographics.

Galsky MD, Oh WK. Galsky MD, et al. Cancer. 2014 Oct 1;120(19):2944-5. doi: 10.1002/cncr.28808. Epub 2014 Jun 25. Cancer. 2014. PMID: 24965362 Free article. No abstract available.

5

Use of crowdsourcing for cancer clinical trial development.

Leiter A, Sablinski T, Diefenbach M, Foster M, Greenberg A, Holland J, Oh WK, Galsky MD. Leiter A, et al. Among authors: galsky md. J Natl Cancer Inst. 2014 Sep 12;106(10):dju258. doi: 10.1093/jnci/dju258. Print 2014 Oct. J Natl Cancer Inst. 2014. PMID: 25217580

6

Geographic accessibility to clinical trials for advanced cancer in the United States.

Galsky MD, Stensland KD, McBride RB, Latif A, Moshier E, Oh WK, Wisnivesky J. Galsky MD, et al. JAMA Intern Med. 2015 Feb;175(2):293-5. doi: 10.1001/jamainternmed.2014.6300. JAMA Intern Med. 2015. PMID: 25437434 No abstract available.

7

The landscape of precision cancer medicine clinical trials in the United States.

Roper N, Stensland KD, Hendricks R, Galsky MD. Roper N, et al. Among authors: galsky md. Cancer Treat Rev. 2015 May;41(5):385-90. doi: 10.1016/j.ctrv.2015.02.009. Epub 2015 Feb 27. Cancer Treat Rev. 2015. PMID: 25864024 Review.

8

Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors.

Khunger M, Rakshit S, Hernandez AV, Pasupuleti V, Glass K, Galsky MD, Grivas P. Khunger M, et al. Among authors: galsky md. Oncologist. 2018 Dec;23(12):1494-1499. doi: 10.1634/theoncologist.2018-0003. Epub 2018 Aug 1. Oncologist. 2018. PMID: 30068783 Free PMC article.

9

Assessing Genitourinary Cancer Clinical Trial Accrual Sufficiency Using Archived Trial Data.

Stensland K, Kaffenberger S, Canes D, Galsky M, Skolarus T, Moinzadeh A. Stensland K, et al. JCO Clin Cancer Inform. 2020 Jul;4:614-622. doi: 10.1200/CCI.20.00031. JCO Clin Cancer Inform. 2020. PMID: 32667822

10

Estimating the rate and reasons of clinical trial failure in urologic oncology.

Stensland KD, DePorto K, Ryan J, Kaffenberger S, Reinstatler LS, Galsky M, Canes D, Skolarus TA, Moinzadeh A. Stensland KD, et al. Urol Oncol. 2021 Mar;39(3):154-160. doi: 10.1016/j.urolonc.2020.10.070. Epub 2020 Nov 27. Urol Oncol. 2021. PMID: 33257221 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

383 results

Search Page

Filters